Goldman Sachs raises its gold price target to $4,900 by end-2026
Investing.com - Berenberg initiated coverage on Eckert & Ziegler SE (EUZ:GR) with a Buy rating and a price target of EUR24.00 on Tuesday.
The research firm cited the company’s strong market position as a supplier to blue-chip customers in the growing nuclear medicine industry as a key factor in its positive outlook.
Berenberg expects Eckert & Ziegler to achieve approximately 10% earnings per share compound annual growth rate from 2025 to 2028, with net earnings margins projected to reach about 18% by 2028, up from an estimated 16.7% in 2025.
The firm views the company’s current valuation at 22 times 2025 estimated earnings (a PEG ratio of 2.2x) as compelling, noting the company’s established position as a leading global player in an industry with high entry barriers.
Berenberg believes Eckert & Ziegler is well-positioned to benefit from increasing demand for isotopes such as Actinium-225, used in oncology drug development, and from its international expansion efforts in regions including the US and China.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.